In the search for more effective therapies for breast cancer, researchers from Rutgers Cancer Institute of New Jersey and Rutgers University are targeting opioid receptors to potentially reduce the development and spread of certain breast cancer subtypes.
Phase 1b and phase 2 clinical trials examining pembrolizumab for advanced small cell lung cancer who received two or more lines of prior treatment show anti-tumor activity with durable responses and manageable toxicity. Rutgers Cancer Institute of New Jersey's Dr. Janice Mehnert, an investigator on the work, shares more.
Colorectal cancer is the third leading cancer in both new cases and cancer deaths in the United States. While colorectal cancer incidence declined 3.7 percent annually from 2006 to 2015 for those 55 and older, rates have increased 1.8 percent annually for those younger than age 55. According to a Rutgers Cancer Institute of New Jersey expert, there is still a lot of work to be done.
Researchers at Rutgers Cancer Institute of New Jersey and University of Virginia Center for Behavioral Health and Technology have found that a web-based intervention targeting sun protection behaviors and skin self-examinations in melanoma patients is effective in promoting short-term improvements in these activities.
Those with B-cell lymphomas that do not respond to standard therapies now have another treatment option in New Jersey, as CAR-T cell therapy is now being offered at Robert Wood Johnson University Hospital New Brunswick, an RWJBarnabas Health facility, in conjunction with Rutgers Cancer Institute of New Jersey.
Investigators at Rutgers Cancer Institute of New Jersey have found that a surgical procedure, when used as a first-line therapy for a form of testicular cancer known as seminoma, is associated with favorable survival rates.
Research from Rutgers Cancer Institute of New Jersey examined a potential approach to cancer therapy that disrupts a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy. Using laboratory models for LKB1-deficient KRAS-mutant non-small cell lung cancer, they found that autophagy ablation reduced the frequency of tumor initiation and tumor growth in Lkb1-deficient lung tumors.
Rutgers Cancer Institute of New Jersey researcher Sharon R. Pine, PhD, has received a $200,000 Lung Cancer Discovery Award from the American Lung Association to examine potential new treatment options for patients with a sub-type of non-small cell lung cancer.
Research from Rutgers Cancer Institute of New Jersey shows improved overall survival at five years for pediatric patients with early-stage Hodgkin lymphoma when treated with chemotherapy followed by radiotherapy versus chemotherapy alone.
Investigators at Rutgers Cancer Institute have uncovered that some mutations detected with targeted genome sequencing of patients with solid tumors are a result of a group of hematologic malignancies known as myeloproliferative neoplasms (MPN). This discovery may have direct implications for treating cancer patients who may have a solid tumor as well as a MPN.
Rutgers Cancer Institute experts share more about the importance of preventative screenings for colorectal and lung cancers.
Rutgers Cancer Institute of New Jersey is leading a research study aimed at improving skin cancer protection behaviors in young adults through an online intervention.
An investigational immunotherapy drug has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. The lead investigator from Rutgers Cancer Institute of New Jersey shares more on the phase 1 trial.
Systems biology analyses by Rutgers Cancer Institute of New Jersey researchers examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma suggest calcium signaling may have an influence in addressing this treatment obstacle.
A $2 million grant from the National Cancer Institute will support the expansion of Rutgers Cancer Institute of New Jersey research focused on sun protective behaviors among young melanoma survivors -- an intervention delivered through social media.
Research from investigators at Rutgers Cancer Institute of New Jersey shows that the cell recycling process of autophagy maintains an important tumor nutrient, arginine, in the blood supply, identifying a metabolic vulnerability of cancer.
To address challenges with clinical trial access for pediatric and young adult cancer patients, Rutgers Cancer Institute of New Jersey will utilize a $50,000 infrastructure grant from the St. Baldrick’s Foundation to provide additional support for a clinical research nurse.
Rutgers Cancer Institute of New Jersey, in collaboration with Robert Wood Johnson University Hospital (RWJUH) – New Brunswick, is the first in the Garden State to administer a form of targeted cancer treatment known as peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors that have spread beyond the initial tumor site.
A Rutgers Cancer Institute of New Jersey researcher has received a $150,000 grant from the Lung Cancer Research Foundation to investigateautophagy in the development of lung cancers driven by mutations in tumor suppressors known as LKB1 and oncogene KRAS.
A number of physicians at Rutgers Cancer Institute of New Jersey – the state’s only National Cancer Institute-designated Comprehensive Cancer Center – have been recognized by New Jersey Monthly magazine as a ‘Jersey Choice Top Doctor.’
In the U.S., lung cancer remains the leading cause of cancer death among both men and women. The primary reason for high death rates for lung cancer is the fact that this disease is typically detected in very late stages. A Rutgers University expert weighs in on new screening resources to combat the disease.
Mentored by scientists from Rutgers Cancer Institute of New Jersey at Princeton University and Rutgers University, early-career investigators received a combined $1,600,000 in funding to support basic science research that could impact breast, colorectal, lung and other cancers. The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).
Can the combination of radiation therapy with an oncolytic virus treatment better boost the body’s immune response to melanoma than either treatment on its own? Investigators from Rutgers Cancer Institute of New Jersey further explored that question in work presented at the ASTRO Annual Meeting.
Richard Drachtman, MD, clinical section chief of the Pediatric Hematology/Oncology Division at Rutgers Cancer Institute of New Jersey, has been named the 2018 recipient of the Melvyn H. Motolinsky Research Foundation Distinguished Service Award in recognition of his accomplishments and leadership in the field of pediatric cancer and blood disorders.
The Biospecimen Repository and Histopathology Service shared resource at Rutgers Cancer Institute of New Jersey has received accreditation from the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
Newly published results of a study examining men with locally or regionally advanced prostate cancer show those treated with a radical prostatectomy followed by radiation treatment have a lower risk of death from prostate cancer and improved overall survival in comparison to those treated with radiation plus androgen deprivation therapy. The work was led by a Rutgers Cancer Institute of New Jersey researcher in collaboration with other regional investigators.
Analysis by investigators at Rutgers Cancer Institute of New Jersey further examines tumor evolution through genomic data captured from thousands of cancer tumor samples using a mathematical model.
Sickle cell disease is a common inherited blood disorder, affecting an estimated 100,000 Americans of different racial and ethnic groups. A Rutgers Cancer Institute of New Jersey expert shares more about the importance of early diagnosis and comprehensive management of this disease.
While thyroid cancers are common, they may not be as widely understood as other common cancers such as breast or prostate. A Rutgers Cancer Institute of New Jersey expert shares more about the butterfly-shaped gland in the lower neck and how cancer might present there.
Rutgers Cancer Institute of New Jersey has named M. Michele Blackwood, MD, FACS, as its new Chief of Breast Surgery. Dr. Blackwood, whose surgical expertise is in complex breast malignancies, is currently the Medical Director and Northern Regional Director of Breast Services for RWJBarnabas Health.
During this Gynecologic Cancers Awareness Month, a Rutgers Cancer Institute of New Jersey expert shares info on symptoms and treatment of ovarian cancer.
When it comes to breast cancer subtype in the Garden State, researchers from Rutgers University and the New Jersey State Cancer Registry find that non-Hispanic black women and women between the ages of 20 to 39 have higher rates of triple-negative disease than females aged 50 to 64 and those of other races and ethnicities.
With recent changes in recommendations for PSA testing for prostate cancer, confusion may exist for those considering the screening. A Rutgers Cancer Institute of New Jersey expert shares what one needs to know when discussing the topic with his doctor.
Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care.
A $500,000 grant from the Pancreatic Cancer Action Network will help a Rutgers Cancer Institute of New Jersey physician-scientist explore a biological event associated with a signaling pathway known as Netrin-1 that enables cancer cells to live.
The Hugs for Brady Foundation has announced a $500,000 pledge to Rutgers Cancer Institute of New Jersey to support a dedicated laboratory space for pediatric cancer research.
Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as designated by the National Cancer Institute (NCI), has successfully renewed this designation.
Rutgers Cancer Institute of New Jersey now has additional resources in the fight against pediatric cancers and blood disorders, thanks to a $1 million commitment from Embrace Kids Foundation that will support the recruitment of pediatric cancer research faculty.
A one-year, $100,000 grant awarded to a Rutgers Cancer Institute of New Jersey researcher from the Leukemia Research Foundation will support exploration into an aggressive blood cancer that impacts both children and adults – T-cell acute lymphoblastic leukemia (T-ALL).
With word this week that former PGA Tour golfer Jarrod Lyle is transitioning from treatment for acute myeloid leukemia to palliative care, one might wonder what that form of care entails. A Rutgers Cancer Institute of New Jersey expert shares more about that part of the cancer journey.
Rutgers researchers will benefit from a $250,000 grant from the Gillson Longenbaugh Foundation to help expand the team’s work on neural stem cell interactions and developing antibody therapeutics for cancer treatment.
Rutgers Cancer Institute of New Jersey, the NJ State Cancer Registry and the NJ Department of Health are collaborating on a $26.5 million study examining African-American men and prostate cancer. The ‘RESPOND’ study is being led by the Keck School of Medicine at USC.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have been recognized with a Blue Distinction® Centers for Cancer Care designation as part of the Blue Distinction Specialty Care program.
Aiming to reduce cancer risk, improve the understanding of cancer outcomes, and promote cancer health equity in the most vulnerable populations at the community level, the Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have recruited Anita Y. Kinney, PhD, to two new leadership roles.
Rutgers Cancer Institute of New Jersey researchers have elucidated the mechanism behind an ‘on/off’ switch in the the most commonly mutated gene in human cancer – p53 – findings which they say could lead to a new paradigm in cancer therapeutics.
Cardiac late effects will be the focus of an upcoming ‘Survivors Family Education Night’ hosted by Rutgers Cancer Institute of New Jersey. Supported by a grant from the National Children’s Cancer Society, the event targets pediatric cancer survivors.
Researchers at Rutgers Cancer Institute are exploring the combination of a new anti-cancer vaccine with an immunotherapy drug approved for use in other forms of cancer to determine if the combined treatment can prompt a patient’s natural defenses (the immune system) to attack their cancer and improve their survival.
Several physicians from Rutgers Cancer Institute of New Jersey have been named as a ‘Top Doctor’ or ‘Top Doctor for Cancer Care’ by Castle Connolly Medical Ltd., which publishes resource guides on top healthcare professionals across the nation.
Instead of another tie or tools, give the gift of good health this Father’s Day. As Rutgers Cancer Institute of New Jersey experts note, it’s as simple as encouraging regular health screenings to protect against cancer.
Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction. Those studies were done without selecting patients for KRAS mutations. Investigators from the ECOG-ACRIN Cancer Research Group led by Howard S. Hochster, MD, FACP, associate director for clinical research and director of gastrointestinal oncology at Rutgers Cancer Institute of New Jersey, explored the anti-VEGFR antibody ramucirumab in second-line treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right